Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $5.00 Price Target at UBS Group
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by UBS Group from $12.00 to $5.00 in a research note released on Tuesday,Benzinga reports. UBS Group currently has a buy rating on the biotechnology company’s stock. Other analysts have also issued research reports about the stock. Leerink Partnrs lowered shares of Rocket Pharmaceuticals […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) had its price objective decreased by UBS Group from $12.00 to $5.00 in a research note released on Tuesday,Benzinga reports. UBS Group currently has a buy rating on the biotechnology company’s stock. Other analysts have also issued research reports about the stock. Leerink Partnrs lowered shares of Rocket Pharmaceuticals […]
